Alex Dando
Papers
1
Total Citations
1
H-Index
1
About
Alex Dando is a clinical researcher whose work centers on the treatment of p16-positive oropharyngeal squamous cell carcinoma, a subtype of head and neck cancer strongly linked to HPV. His major contribution lies in comparing the oncological and functional outcomes of transoral robotic surgery (TORS) versus primary radiotherapy for early-stage (T1-2 N0-1) disease. In his most-cited 2025 study, Dando analyzed a cohort of patients treated with either TORS plus neck dissection (with or without adjuvant therapy) or primary radiotherapy, providing critical evidence on survival, swallowing function, and quality of life. This work directly informs the ongoing de-escalation debate in HPV-related oropharyngeal cancer, where the goal is to maintain excellent cure rates while reducing treatment toxicity. Though early in his citation impact, Dando’s research is already shaping clinical decision-making for one of the fastest-rising cancers in younger, healthier patients. His findings are particularly valuable for surgeons and radiation oncologists seeking to personalize treatment based on functional preservation and oncologic safety.
Research Focus
Key Achievements
Top Papers
- 1